drugset / Trial / NCT01077986
Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this study the investigators want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by EGFR and mTOR inhibition in patients with metastatic pancreatic cancer.
Timeline
- Start
- 2009-08
- Primary completion
- 2010-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 600 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 800 mg/m2 | Oral |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Other |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |